Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma.
Satin U et al. J Clin Apher. 2017 Oct 5. doi: 10.1002/jca.21591. [Epub ahead of print].

NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma.
Jeker B et al. Bone Marrow Transplant. 2017 Oct 23. doi: 10.1038/bmt.2017.234. [Epub ahead of print].

Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
Ensile H et al. Br J Haematol. 2017 Sep 29. doi: 10.1111/bjh.14920. [Epub ahead of print].

Impact of Autologous Stem Cell Transplantation on Blood Pressure and Renal Function in Multiple Myeloma Patients.
Balsam L et al. J Natl Med Assoc. 2017 Autumn;109(3):182-191. doi: 10.1016/j.jnma.2017.02.010. Epub 2017 Mar 30.

Long-Term Follow-Up of a “Donor” Versus “No Donor” Comparison in Multiple Myeloma Patients at First Relapse after Failing Autologous Transplantation.
Patriarca F et al. Biol Blood Marrow Transplant. 2017 Oct 12. pii: S1083-8791(17)30773-5. doi: 10.1016/j.bbmt.2017.10.014. [Epub ahead of print].

Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
Zannetti BA et al. Ann Hematol. 2017 Oct 24. doi: 10.1007/s00277-017-3140-5. [Epub ahead of print].

‘Real-world’ Australian experience of pomalidomide for relapsed and refractory myeloma.
Scott A et al. Leuk Lymphoma. 2017 Oct 12:1-3. doi: 10.1080/10428194.2017.1387911. [Epub ahead of print].